Cargando…

Serum spexin differed in newly diagnosed type 2 diabetes patients according to body mass index and increased with the improvement of metabolic status

OBJECTIVE: The aim of this study was to explore serum spexin levels in newly diagnosed type 2 diabetes mellitus (T2DM) patients with different body mass indexes (BMIs) and to investigate the changes of spexin after improvement of metabolic indicators. METHODS: A total of 323 newly diagnosed T2DM pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Liping, Yan, Shuai, Huang, Yunhong, Yang, Jiaying, Peng, Yongde, Wang, Yufan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794602/
https://www.ncbi.nlm.nih.gov/pubmed/36589830
http://dx.doi.org/10.3389/fendo.2022.1086497
_version_ 1784860074368303104
author Gu, Liping
Yan, Shuai
Huang, Yunhong
Yang, Jiaying
Peng, Yongde
Wang, Yufan
author_facet Gu, Liping
Yan, Shuai
Huang, Yunhong
Yang, Jiaying
Peng, Yongde
Wang, Yufan
author_sort Gu, Liping
collection PubMed
description OBJECTIVE: The aim of this study was to explore serum spexin levels in newly diagnosed type 2 diabetes mellitus (T2DM) patients with different body mass indexes (BMIs) and to investigate the changes of spexin after improvement of metabolic indicators. METHODS: A total of 323 newly diagnosed T2DM patients from national Metabolic Management Center (MMC) in Shanghai General Hospital were recruited. T2DM patients were categorized into three groups: diabetes with obesity group (DM-OB group, BMI≥28 kg/m(2), n=89), diabetes with overweight group (DM-OV group, 24≤BMI<28 kg/m(2), n=161), and diabetes with normal weight group (DM-NW group, 18≤BMI<24 kg/m(2), n=73). In addition, 41 volunteers with normal glucose tolerance (NGT) were used as controls. Spexin and metabolic parameters were compared at baseline, and changes after MMC follow-up in 100 DM patients were investigated. RESULTS: In the DM-OB group, the level of spexin was significantly lower than that in the DM-OV group and the DM-NW group (P < 0.01). Spexin was significantly negatively related to body mass index (BMI, β=-0.214, P<0.001), waist circumference (β=-0.249, P<0.001), visceral fat area (VFA, β=-0.214, P<0.001), and subcutaneous fat area (SFA, β=-0.265, P<0.001) after adjustment for age and sex. Among all the metabolic indicators, the decline in BMI in the DM-OB group was the most obvious among those in the three groups (-3.7 ± 0.8 kg/m(2) vs. -0.9 ± 0.3 kg/m(2) vs. 0.7 ± 0.6 kg/m(2), P<0.01) after one year of MMC standardized management. The serum spexin level in the DM-OB group increased the most (1.00 ± 0.10 ng/mL vs. 0.49 ± 0.06 ng/mL in DM-OV group and 0.58 ± 0.09 ng/mL in DM-NW group, P < 0.001). CONCLUSIONS: Serum spexin differed in newly diagnosed T2DM patients according to BMI and was lowest in the DM-OB group. With the improvement of metabolic indicators, especially the decline in BMI, serum spexin increased significantly after MMC management.
format Online
Article
Text
id pubmed-9794602
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97946022022-12-29 Serum spexin differed in newly diagnosed type 2 diabetes patients according to body mass index and increased with the improvement of metabolic status Gu, Liping Yan, Shuai Huang, Yunhong Yang, Jiaying Peng, Yongde Wang, Yufan Front Endocrinol (Lausanne) Endocrinology OBJECTIVE: The aim of this study was to explore serum spexin levels in newly diagnosed type 2 diabetes mellitus (T2DM) patients with different body mass indexes (BMIs) and to investigate the changes of spexin after improvement of metabolic indicators. METHODS: A total of 323 newly diagnosed T2DM patients from national Metabolic Management Center (MMC) in Shanghai General Hospital were recruited. T2DM patients were categorized into three groups: diabetes with obesity group (DM-OB group, BMI≥28 kg/m(2), n=89), diabetes with overweight group (DM-OV group, 24≤BMI<28 kg/m(2), n=161), and diabetes with normal weight group (DM-NW group, 18≤BMI<24 kg/m(2), n=73). In addition, 41 volunteers with normal glucose tolerance (NGT) were used as controls. Spexin and metabolic parameters were compared at baseline, and changes after MMC follow-up in 100 DM patients were investigated. RESULTS: In the DM-OB group, the level of spexin was significantly lower than that in the DM-OV group and the DM-NW group (P < 0.01). Spexin was significantly negatively related to body mass index (BMI, β=-0.214, P<0.001), waist circumference (β=-0.249, P<0.001), visceral fat area (VFA, β=-0.214, P<0.001), and subcutaneous fat area (SFA, β=-0.265, P<0.001) after adjustment for age and sex. Among all the metabolic indicators, the decline in BMI in the DM-OB group was the most obvious among those in the three groups (-3.7 ± 0.8 kg/m(2) vs. -0.9 ± 0.3 kg/m(2) vs. 0.7 ± 0.6 kg/m(2), P<0.01) after one year of MMC standardized management. The serum spexin level in the DM-OB group increased the most (1.00 ± 0.10 ng/mL vs. 0.49 ± 0.06 ng/mL in DM-OV group and 0.58 ± 0.09 ng/mL in DM-NW group, P < 0.001). CONCLUSIONS: Serum spexin differed in newly diagnosed T2DM patients according to BMI and was lowest in the DM-OB group. With the improvement of metabolic indicators, especially the decline in BMI, serum spexin increased significantly after MMC management. Frontiers Media S.A. 2022-12-14 /pmc/articles/PMC9794602/ /pubmed/36589830 http://dx.doi.org/10.3389/fendo.2022.1086497 Text en Copyright © 2022 Gu, Yan, Huang, Yang, Peng and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Gu, Liping
Yan, Shuai
Huang, Yunhong
Yang, Jiaying
Peng, Yongde
Wang, Yufan
Serum spexin differed in newly diagnosed type 2 diabetes patients according to body mass index and increased with the improvement of metabolic status
title Serum spexin differed in newly diagnosed type 2 diabetes patients according to body mass index and increased with the improvement of metabolic status
title_full Serum spexin differed in newly diagnosed type 2 diabetes patients according to body mass index and increased with the improvement of metabolic status
title_fullStr Serum spexin differed in newly diagnosed type 2 diabetes patients according to body mass index and increased with the improvement of metabolic status
title_full_unstemmed Serum spexin differed in newly diagnosed type 2 diabetes patients according to body mass index and increased with the improvement of metabolic status
title_short Serum spexin differed in newly diagnosed type 2 diabetes patients according to body mass index and increased with the improvement of metabolic status
title_sort serum spexin differed in newly diagnosed type 2 diabetes patients according to body mass index and increased with the improvement of metabolic status
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794602/
https://www.ncbi.nlm.nih.gov/pubmed/36589830
http://dx.doi.org/10.3389/fendo.2022.1086497
work_keys_str_mv AT guliping serumspexindifferedinnewlydiagnosedtype2diabetespatientsaccordingtobodymassindexandincreasedwiththeimprovementofmetabolicstatus
AT yanshuai serumspexindifferedinnewlydiagnosedtype2diabetespatientsaccordingtobodymassindexandincreasedwiththeimprovementofmetabolicstatus
AT huangyunhong serumspexindifferedinnewlydiagnosedtype2diabetespatientsaccordingtobodymassindexandincreasedwiththeimprovementofmetabolicstatus
AT yangjiaying serumspexindifferedinnewlydiagnosedtype2diabetespatientsaccordingtobodymassindexandincreasedwiththeimprovementofmetabolicstatus
AT pengyongde serumspexindifferedinnewlydiagnosedtype2diabetespatientsaccordingtobodymassindexandincreasedwiththeimprovementofmetabolicstatus
AT wangyufan serumspexindifferedinnewlydiagnosedtype2diabetespatientsaccordingtobodymassindexandincreasedwiththeimprovementofmetabolicstatus